Literature DB >> 25266485

Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.

Y-T Li1, H-F Cai, Z-L Zhang.   

Abstract

SUMMARY: We performed a systematic review and meta-analysis of randomized clinical trials. Early administration of bisphosphonates (BPs) after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.
INTRODUCTION: Bisphosphonates (BPs) are widely used in the prophylaxis and treatment of osteoporosis. However, early administration of BPs after surgical repair of a fracture may limit the reserve capacity of bone to heal. The aim of this review and meta-analysis was to analyze the benefits and adverse effects of early administration of BPs and give recommendations regarding when BPs should be utilized.
METHODS: We identified randomized controlled trials comparing the early administration of BPs to placebo, delayed BP treatment, or no therapy in adult patients after surgery. The search was performed in PubMed, the Cochrane Library, and Embase.
RESULTS: Ten studies with 2888 patients were included. Four trials used alendronate, three trials used zoledronic, two trials used risedronate, and one trial used etidronate. Early administration of BPs was considered less than 3 months after surgery. Patients treated with BP therapy had no significant differences in radiological fracture healing times compared with patients in the control group (mean difference [MD] 0.47, 95% confidence interval [CI] -2.75 to 3.69). There were also no significant differences in the rate of delay or nonunion of fracture healing (odds ratio [OR] 0.98, 95% CI 0.64 to 1.50). However, the bone mineral density (BMD) of total hips did significantly improve after 12 months of treatment with BPs. And most bone turnover markers of patients in the study group were significantly decreased.
CONCLUSIONS: Early administration of BPs after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, according to the changes in BMD and bone turnover markers, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266485     DOI: 10.1007/s00198-014-2903-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  50 in total

Review 1.  Bone turnover markers.

Authors:  Penelope Coates
Journal:  Aust Fam Physician       Date:  2013-05

2.  Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?

Authors:  Yong-Chan Ha; Myung-Rae Cho; Ki Hong Park; Shin-Yoon Kim; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2010-09-24       Impact factor: 4.176

3.  The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery.

Authors:  Chao Li; Hui-Ren Wang; Xi-Lei Li; Xiao-Gang Zhou; Jian Dong
Journal:  Acta Neurochir (Wien)       Date:  2012-04       Impact factor: 2.216

4.  Effect of zoledronic acid in an L6-L7 rabbit spine fusion model.

Authors:  Rick Bransford; Elisabeth Goergens; Julie Briody; Negin Amanat; Andrew Cree; David Little
Journal:  Eur Spine J       Date:  2006-09-12       Impact factor: 3.134

5.  Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.

Authors:  J Goldhahn; J-M Féron; J Kanis; S Papapoulos; J-Y Reginster; R Rizzoli; W Dere; B Mitlak; Y Tsouderos; S Boonen
Journal:  Calcif Tissue Int       Date:  2012-03-28       Impact factor: 4.333

6.  Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone.

Authors:  A E Goodship; P C Walker; D McNally; T Chambers; J R Green
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

7.  [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].

Authors:  Faik Altintaş; Afşar Timuçin Ozkut; Tahsin Beyzadeoğlu; Abdullah Eren; Melih Güven
Journal:  Acta Orthop Traumatol Turc       Date:  2007       Impact factor: 1.511

8.  A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.

Authors:  Hui Li; Hui Xie; Wei Liu; Rong Hu; Bi Huang; Yan-Fei Tan; Kang Xu; Zhi-Feng Sheng; Hou-De Zhou; Xian-Ping Wu; Xiang-Hang Luo
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

9.  New method for removing type 2 copper from Rhus laccase.

Authors:  A S Klemens; D R McMillin
Journal:  J Inorg Biochem       Date:  1990-02       Impact factor: 4.155

10.  Beneficial effect of etidronate therapy in immobilized hip fracture patients.

Authors:  Yoshihiro Sato; Tomohiro Kanoko; Hajime Yasuda; Kei Satoh; Jun Iwamoto
Journal:  Am J Phys Med Rehabil       Date:  2004-04       Impact factor: 2.159

View more
  24 in total

1.  After the fall: improving osteoporosis treatment following hip fracture.

Authors:  B W Kuiper; S Graybill; J M Tate; N Kaufman; D Bersabe
Journal:  Osteoporos Int       Date:  2018-02-20       Impact factor: 4.507

2.  Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion.

Authors:  Jian Chen; Lipeng Yu; Lixin Chen; Xuan Wu; Pengyu Tang; Jian Yin; Tao Jiang; Guoyong Yin; Jin Fan
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

Review 3.  Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures.

Authors:  Byung-Woo Min; Kwang-Soon Song; Ki-Cheor Bae; Chul-Hyun Cho; Eun-Suck Son; Kyung-Jae Lee
Journal:  Hip Pelvis       Date:  2015-03-31

4.  The analysis of alendronate action in bone fracture healing in rats.

Authors:  Francisco de Assis Serra Baima Filho; Priscylla Gouveia Mendonça; Gyl Eanes Barros Silva; Orlando José Dos Santos; João Batista Santos Garcia; Maria do Socorro de Sousa Cartagenes
Journal:  J Clin Orthop Trauma       Date:  2020-07-29

5.  Determining the pharmacologic window of bisphosphonates that mitigates severe injury-induced osteoporosis and muscle calcification, while preserving fracture repair.

Authors:  M Saito; S N Moore-Lotridge; S Uppuganti; S Egawa; T Yoshii; J P Robinette; S L Posey; B H Y Gibson; H A Cole; G D Hawley; S A Guelcher; S B Tanner; J R McCarthy; J S Nyman; J G Schoenecker
Journal:  Osteoporos Int       Date:  2021-10-31       Impact factor: 5.071

Review 6.  How do bisphosphonates affect fracture healing?

Authors:  Stephen L Kates; Cheryl L Ackert-Bicknell
Journal:  Injury       Date:  2016-01       Impact factor: 2.586

7.  Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.

Authors:  Catherine Van Poznak; Evan L Reynolds; Cherry L Estilo; Mimi Hu; Bryan Paul Schneider; Daniel L Hertz; Christina Gersch; Jacklyn Thibert; Dafydd Thomas; Mousumi Banerjee; James M Rae; Daniel F Hayes
Journal:  Oral Dis       Date:  2020-12-14       Impact factor: 3.511

8.  Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group.

Authors:  S L Silverman; E S Kupperman; S V Bukata
Journal:  Osteoporos Int       Date:  2016-04-25       Impact factor: 4.507

9.  Intravenous bisphosphonate therapy does not delay fracture healing in inter-trochanteric femur fractures - A randomised controlled study.

Authors:  Harsh Jalan; Ramesh Perumal; Suresh Prabhu; Sivakumar Palanivelayutham; Vibhu Krishnan Viswanathan; S Rajasekaran
Journal:  J Clin Orthop Trauma       Date:  2021-06-08

Review 10.  Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey.

Authors:  Gulistan Bahat; Nezahat Muge Catikkas; Mehmet Akif Karan; Jean Yves Reginster
Journal:  Arch Osteoporos       Date:  2021-06-26       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.